Articles On Genetic Signatures (ASX:GSS)

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

ShareCafeHidden Gems Webinar Recap – PHL, LBY, BCB & GSS Catch up on the full webinar with presentations from Propell Holdings (ASX: PHL), Laybuy (ASX: LBY), Bowen Coking Coal (ASX: BCB) & Genetic Signatures (ASX: GSS) Hidden Gems...

ShareCafeTest kits for infectious disease John Melki – CEO & Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3ba...

ShareCafeGenetic Signatures: Australia’s Rapid Growth Diagnostics Company by Colin Hay   Genetic Signatures’ growth strategy is about building its customer numbers, the range of its proprietary tests for COVID-19 and a range of viral, proto...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary Trajan Group Holdings made a strong debut on ASX on June 7, 2021. The MedTech company successfully raised AU$90 million via IPO at a market cap of AU$220 million. The company is expected to achieve revenue of AU$75 million in...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary Several ASX-listed companies have released their quarterly results in the last few days, attracting significant market attention. Genetic Signatures reported strong quarterly and YTD sales driven by the increasing demand for it...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

ShareCafeThe Week that Was – March 1-5, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, he...

ShareCafeGenetic Signatures Leverages New Screening Targets to EU and US Markets Following the announcement of its first substantial profit (for the first half of full year 2021), GeneticSignatures (ASX: GSS) a specialist molecular diagnost...

COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or tests are pushing on. The outbreak of the pandemic caused a number of ASX companies (big and small) to pivot to fighting COVID-19. In the last f...

The Genetic Signatures Ltd (ASX: GSS) share price was on form on Monday. At one stage the molecular diagnostics company’s shares were up as much as 10% to $1.83. The Genetic Signatures share price ultimately closed the day 6% higher at $1....

ShareCafeGenetic Signatures (ASX:GSS) – Hidden Gems Webinar Presentation – 12/2/21   Presenter – John Melki – Chief Executive Officer and Director – Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the deve...

ShareCafeHidden Gems Webinar Recap – Chester Asset Management, GSS, SVL, BPH – 12/2/21 Catch up on the full webinar with presentations from Chester Asset Management, Genetic Signatures (ASX:GSS), Silver Mines Limited (ASX:SVL) & BPH En...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

The Genetic Signatures Ltd (ASX: GSS) share price has been pushing higher with the market today. In afternoon trade the specialist molecular diagnostics company’s shares are up 3% to $1.96. Though, at one stage today, the Genetic Signature...

Summary Genetic Signatures has acquired Boston Medical Center (BMC) for the supply of its SARS-CoV-2 detection kits. The new agreement will offer BMC with an increased testing capability. The Company also highlighted that the broader...

The Genetic Signatures Ltd (ASX: GSS) share price is rocketing higher on Wednesday after the release of an announcement. In afternoon trade the specialist molecular diagnostics company’s shares are up almost 25% to $2.12. Why is the Geneti...

The market may be struggling on Thursday, but that hasn’t stopped the Genetic Signatures Ltd (ASX: GSS) share price from charging higher. In afternoon trade the specialist molecular diagnostics company’s shares are up over 5% to $1.99 Why...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a disappointing note. At the time of writing the benchmark index is down 0.9% to 5,819.5 points. Four shares that have not let that hold them back a...

ShareCafeGenetic Signatures – ShareCafe Hidden Gems Webinar Presentation   Presenter – John Melki – CEO & Director – Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseas...

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Two COVID-19 antibody kits have failed post-market testing, raising more questions about the 20 point-of-care kits approved for sale in Australia. Four of the 20 point-of-care tests (PoCT) available in Australia have now failed independent...

Less than a fortnight ago Finfeed noted Genetic Signature Ltd’s (ASX: GSS) news that it had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19. Managem...

This could be the best investment opportunity that Australian investors have had in a decade. Those are the words of portfolio managers from Perennial Value Management. According to its latest monthly report, the investment company’s portf...

A new rapid testing kit that can detect the virus which causes Covid-19 has been given the tick of approval from the Therapeutic Goods Administration (TGA). Genetic Signatures' (ASX: GSS) SARS-CoV-2 Detection Kit has been approved for inc...

Australian biotech Genetic Signatures’ (ASX:GSS) is now able to start selling its recently developed COVID-19 diagnostic kit, after it was approved for sale in Australia. The EasyScreen SARS-CoV-2 Detection Kit has been approved to be liste...

14 Apr 2020 - Genetic Signatures (ASX:GSS) has received notice from the Therapeutic Goods Administration (“TGA”) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to…

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

The market for COVID-19 diagnostic kits is much broader than just the health sector, as miners and other industries begin to compete for tests with governments. But where diagnostic tests normally require at minimum several months of patien...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

Specialist molecular diagnostics company Genetic Signatures (ASX: GSS) is sending its first shipments of a new Covid-19 testing kit to labs in Europe and Australia, with its manufacturing facilities in Sydney gearing up for "anticipated ini...

Shares in Genetic Signatures Limited (ASX:GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-...

Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScr...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

As the coronavirus death toll rises to more than 1,000 and the World Health Organisation labels it a global health emergency, share markets are feeling the impact of the outbreak with Australian ASX-listed stocks not immune to the damage. C...

The Aussie market wavers around yesterdays closing mark, following marginal shifts in US indices overnight. By mid-session, the benchmark ASX 200 was just ten points below yesterday’s close of 7,031 points. The US industrial index, the...

We hate to sound like an old school report, but it’s been a year of steady and solid progress for the maker of non-invasive cardiac and pulmonary measuring devices, especially in its key target market of China. Achievements include record r...

As the saying goes, if you can make it in New York you can make it anywhere. But for the home-grown molecular diagnostics house, cracking it in Australia has been the acid test of its greater abilities. “The Australian diagnostic market is...

Health care sector During the past several years, the Australian Health Care Sector had seen rapid development, and as a result it stands out as one of the best health care systems in the world, delivering safe, effective and affordable hea...

This year has been a positive one for ASX small caps. According to Bloomberg, the average small cap has gained just under 5 per cent and some of the major sectors have seen double digit percentage gains. One example is the health sector whi...